Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk of Incident Cancer in Patients with Inflammatory Bowel Disease with Prior Breast Cancer: A Multicenter Cohort Study.
Le Cosquer G, Kirchgesner J, Gilletta De Saint Joseph C, Seksik P, Amiot A, Laharie D, Nachury M, Rouillon C, Abitbol V, Nuzzo A, Nancey S, Fumery M, Biron A, Richard N, Altwegg R, Moussata D, Caron B, Vidon M, Reenaers C, Uzzan M, Reimund JM, Serrero M, Simon M, Benezech A, Goutorbe F, Pelletier AL, Caillo L, Vaysse C, Poullenot F; GETAID. Le Cosquer G, et al. Among authors: reimund jm. Clin Gastroenterol Hepatol. 2024 Nov 5:S1542-3565(24)00981-9. doi: 10.1016/j.cgh.2024.09.034. Online ahead of print. Clin Gastroenterol Hepatol. 2024. PMID: 39505240 Free article.
External validation of serum biomarkers predicting short-term and mid/long-term relapse in patients with Crohn's disease stopping infliximab.
Pierre N, Huynh-Thu VA, Baiwir D, Mazzucchelli G, Fléron M, Trzpiot L, Eppe G, De Pauw E, Laharie D, Satsangi J, Bossuyt P, Vuitton L, Vieujean S, Colombel JF, Meuwis MA, Louis E; GETAID and the SPARE-Biocycle research group. Pierre N, et al. Gut. 2024 Nov 11;73(12):1965-1973. doi: 10.1136/gutjnl-2024-332648. Gut. 2024. PMID: 39134391 Free article. Clinical Trial.
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.
Danese S, Panaccione R, Feagan BG, Afzali A, Rubin DT, Sands BE, Reinisch W, Panés J, Sahoo A, Terry NA, Chan D, Han C, Frustaci ME, Yang Z, Sandborn WJ, Hisamatsu T, Andrews JM, D'Haens GR; GALAXI-1 Study Group. Danese S, et al. Lancet Gastroenterol Hepatol. 2024 Feb;9(2):133-146. doi: 10.1016/S2468-1253(23)00318-7. Epub 2023 Dec 14. Lancet Gastroenterol Hepatol. 2024. PMID: 38104569 Clinical Trial.
118 results